Smitha  Antony, Ph.D.
Smitha Antony, Ph.D.
Staff Scientist

Center for Cancer Research
National Cancer Institute

Building 37, Room 1052
Bethesda, MD 20892
301-451-2057

Dr. Smitha Antony has made substantial contributions in the discovery and optimization of novel topoisomerase inhibitors, the indenoisoquinolines. Her research focuses on human topoisomerase 1 (Top1) and human tyrosyl DNA phosphodiesterase 1 (Tdp1) inhibitors and the development and characterization of the NADPH oxidase 5 (NOX5) monoclonal antibody.

Areas of Expertise
1) oxidant-mediated signaling, 2) NADPH oxidases, 3) topoisomerase inhibitors

Reactive oxygen species (ROS) have been implicated in physiological and pathophysiological signaling pathways, including cancer development and progression. Our laboratory focuses on the role of oxidant-mediated signaling in tumor cell proliferation. We are particularly interested in the epithelial NADPH oxidase (NOX) gene family and are focused on three specific areas of research: a) evaluating the role of the NOX gene family members in tumor cell growth control and angiogenesis; b) examining the role of members of the NOX family in modulating pro-inflammatory, cytokine-related signal transduction in tumor cells; and c) developing novel inhibitors of NOX isoforms and evaluating their potential as cancer therapeutic agents.

Scientific Focus Areas:
Cancer Biology, Clinical Research, Molecular Biology and Biochemistry, Molecular Pharmacology

View Dr. Antony's Full PubMed Summary.

Selected Key Publications
  1. Antony S, Wu Y, Hewitt SM, Anver MR, Butcher D, Jiang G, Meitzler JL, Liu H, Juhasz A, Lu J, Roy KK, Doroshow JH.
    Free Radic. Biol. Med. 65: 497-508, 2013. [ Journal Article ]
  2. Wu Y, Lu J, Antony S, Juhasz A, Liu H, Jiang G, Meitzler JL, Hollingshead M, Haines DC, Butcher D, Roy K, Doroshow JH.
    J. Immunol. 190: 1859-72, 2013. [ Journal Article ]
  3. Das BB, Antony S, Gupta S, Dexheimer TS, Redon CE, Garfield S, Shiloh Y, Pommier Y.
    EMBO J. 28: 3667-80, 2009. [ Journal Article ]
  4. Antony S, Agama KK, Miao ZH, Takagi K, Wright MH, Robles AI, Varticovski L, Nagarajan M, Morrell A, Cushman M, Pommier Y.
    Cancer Res. 67: 10397-405, 2007. [ Journal Article ]
  5. Antony S, Marchand C, Stephen AG, Thibaut L, Agama KK, Fisher RJ, Pommier Y.
    Nucleic Acids Res. 35: 4474-84, 2007. [ Journal Article ]

Dr. Smitha Antony is a staff scientist in the Oxidative Signaling and Molecular Therapeutics Group at the National Cancer Institute (NCI), NIH. She received her Ph.D. in microbiology and cell biology in 2001 from the Indian Institute of Science. Dr. Antony joined the NCI in 2002 and has made substantial contributions in the discovery and optimization of novel topoisomerase inhibitors, the indenoisoquinolines. Two indenoisoquinoline derivatives are in clinical trials at the NIH with histone γ-H2AX and Top1 levels used as pharmacodynamic biomarkers.

Dr. Antony is the recipient of the Federal Technology Transfer Award and the NCI Certificate of Appreciation for recognition of outstanding contributions to research innovation for her work on human topoisomerase I (Top1) and human tyrosyl DNA phosphodiesterase I (Tdp1) inhibitors and the development and characterization of the NADPH oxidase 5 (NOX5) monoclonal antibody. Dr. Antony has co-authored many publications in the field of DNA damage and repair and holds several patents for inhibitors of DNA topoisomerases.

Summary

Dr. Smitha Antony has made substantial contributions in the discovery and optimization of novel topoisomerase inhibitors, the indenoisoquinolines. Her research focuses on human topoisomerase 1 (Top1) and human tyrosyl DNA phosphodiesterase 1 (Tdp1) inhibitors and the development and characterization of the NADPH oxidase 5 (NOX5) monoclonal antibody.

Areas of Expertise
1) oxidant-mediated signaling, 2) NADPH oxidases, 3) topoisomerase inhibitors

Research

Reactive oxygen species (ROS) have been implicated in physiological and pathophysiological signaling pathways, including cancer development and progression. Our laboratory focuses on the role of oxidant-mediated signaling in tumor cell proliferation. We are particularly interested in the epithelial NADPH oxidase (NOX) gene family and are focused on three specific areas of research: a) evaluating the role of the NOX gene family members in tumor cell growth control and angiogenesis; b) examining the role of members of the NOX family in modulating pro-inflammatory, cytokine-related signal transduction in tumor cells; and c) developing novel inhibitors of NOX isoforms and evaluating their potential as cancer therapeutic agents.

Scientific Focus Areas:
Cancer Biology, Clinical Research, Molecular Biology and Biochemistry, Molecular Pharmacology

Publications

View Dr. Antony's Full PubMed Summary.

Selected Key Publications
  1. Antony S, Wu Y, Hewitt SM, Anver MR, Butcher D, Jiang G, Meitzler JL, Liu H, Juhasz A, Lu J, Roy KK, Doroshow JH.
    Free Radic. Biol. Med. 65: 497-508, 2013. [ Journal Article ]
  2. Wu Y, Lu J, Antony S, Juhasz A, Liu H, Jiang G, Meitzler JL, Hollingshead M, Haines DC, Butcher D, Roy K, Doroshow JH.
    J. Immunol. 190: 1859-72, 2013. [ Journal Article ]
  3. Das BB, Antony S, Gupta S, Dexheimer TS, Redon CE, Garfield S, Shiloh Y, Pommier Y.
    EMBO J. 28: 3667-80, 2009. [ Journal Article ]
  4. Antony S, Agama KK, Miao ZH, Takagi K, Wright MH, Robles AI, Varticovski L, Nagarajan M, Morrell A, Cushman M, Pommier Y.
    Cancer Res. 67: 10397-405, 2007. [ Journal Article ]
  5. Antony S, Marchand C, Stephen AG, Thibaut L, Agama KK, Fisher RJ, Pommier Y.
    Nucleic Acids Res. 35: 4474-84, 2007. [ Journal Article ]

Biography

Dr. Smitha Antony is a staff scientist in the Oxidative Signaling and Molecular Therapeutics Group at the National Cancer Institute (NCI), NIH. She received her Ph.D. in microbiology and cell biology in 2001 from the Indian Institute of Science. Dr. Antony joined the NCI in 2002 and has made substantial contributions in the discovery and optimization of novel topoisomerase inhibitors, the indenoisoquinolines. Two indenoisoquinoline derivatives are in clinical trials at the NIH with histone γ-H2AX and Top1 levels used as pharmacodynamic biomarkers.

Dr. Antony is the recipient of the Federal Technology Transfer Award and the NCI Certificate of Appreciation for recognition of outstanding contributions to research innovation for her work on human topoisomerase I (Top1) and human tyrosyl DNA phosphodiesterase I (Tdp1) inhibitors and the development and characterization of the NADPH oxidase 5 (NOX5) monoclonal antibody. Dr. Antony has co-authored many publications in the field of DNA damage and repair and holds several patents for inhibitors of DNA topoisomerases.